Skip to main content
Full access
Letter to the Editor
Published Online: 1 June 2004

Polyuria After Olanzapine Overdose

Publication: American Journal of Psychiatry
To the Editor: We report the case of a patient with a history of borderline personality disorder who developed polyuria after an olanzapine overdose.
Adam, a 17-year-old boy, was treated with prazepam and olanzapine, 5 mg b.i.d. He was admitted to our intensive care unit after he had ingested 15 tablets (75 mg) of olanzapine and 7.5 mg of prazepam in a suicide attempt. He had no history of polydipsia. A comprehensive drug screen detected no other substances. He had mild CNS depression with otherwise normal vital signs. Within the first 24 hours of admission, Adam developed a high urinary output (5400 ml/24 hours), with diluted urine. At that time, his urine density was 1.004, his urine osmolality was 166 mosmol/kg H2O, and his serum osmolality was 287 mosmol/kg H2O. His sodium blood level rose from 132 mmol/liter at admission to 141 mmol/liter when Adam was polyuric. His glucose blood level was within the normal range. His blood concentration of ADH was 3.1 pg/ml (normal range=0.0–8.0), and his thyroid-stimulating hormone level was 6.01 μU/ml (normal range=0.2–3.5), with normal total triiodothyronine and thyroxine values. Adam’s polyuria corrected after the intravenous administration of 4 μg of desmopressin (and 2 μg 12 hours later). He was discharged from the intensive care unit on day 3. No recurrence of polyuria was noted at the 1-month follow-up. Magnetic resonance imaging of the hypothalamic-pituitary area, performed 2 months after discharge, was normal.
The constellation of polyuria, hyposmolar urine (166 mosmol/kg H2O), normosmolar plasma, and an increasing level of serum sodium supports the diagnosis of diabetes insipidus in our patient. The rapid resolution of polyuria after administration of a small dose of desmopressin (total of 6 μg in 12 hours) supports the central origin of diabetes insipidus because desmopressin decreases urinary output in central but not in nephrogenic diabetes insipidus (1). Additionally, urine osmolalities lower than 200 mosmol/kg H2O are uncommonly seen in nephrogenic diabetes insipidus (2). The low normal level of ADH in this patient probably represents early or partial central diabetes insipidus.
Although olanzapine is considered to be a safe agent, there are several reports associating it with the development of hyperglycemia, diabetes mellitus (3), and weight gain (4). To our knowledge, olanzapine has not been associated with the development of central or nephrogenic diabetes insipidus. Although schizophrenia has been reported to be associated with polyuria, diabetes insipidus is usually related to lithium therapy and is then of the nephrogenic type. Of note is that olanzapine is chemically related to clozapine, which has been linked to the occurrence of nephrogenic diabetes insipidus (5). We conclude that diabetes insipidus can possibly occur with high doses of olanzapine.

References

1.
Singer I, Oster JR, Fishman LM: The management of diabetes insipidus in adults. Arch Intern Med 1997; 157:1293–1301
2.
Geheb MA: Clinical approach to the hyperosmolar patient. Crit Care Clin 1987; 3:797–815
3.
Bloch Y, Vardi O, Mendlovic S, Levkovitz Y, Gothelf D, Ratzoni G: Hyperglycemia from olanzapine treatment in adolescents. J Child Adolesc Psychopharmacol 2003; 13:97–102
4.
Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, Garcia-Portilla MP, Fernandez I, Hernandez G: Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003; 62:77–88
5.
Bendz H, Aurell M: Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf 1999; 21:449–456

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1130
PubMed: 15169711

History

Published online: 1 June 2004
Published in print: June 2004

Authors

Affiliations

XAVIER WITTEBOLE, M.D.
ANTONIOS LIOLIOS, M.D.
PHILIPPE HANTSON, M.D., Ph.D.
Brussels, Belgium

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share